Here are three things to know.
1. Viralytics, a Sydney, Australia-based biotech company, uses viruses to detect and kill cancer cells.
2. Under the terms of the deal, Merck will pay 1.75 Australian dollars ($1.37) per share for the company.
3. “We are eager to further build on Viralytics’s science as we continue our efforts to harness the immune system to improve long-term disease control and survival outcomes for people with cancer,” Roy Baynes, MD, PhD, senior vice president and head of global clinical development, CMO of Merck Research Laboratories, said in a press release.
More articles on supply chain:
Amazon quietly launches exclusive OTC product line: 7 things to know
AbbVie, Voyager ink $69M deal to develop Alzheimer’s drug
Roche’s diabetes app recalled over software bug: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
